This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Lung Cancer
  • /
  • Early plasma circulating tumor DNA (ctDNA) changes...
Journal

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Read time: 1 mins
Published:24th Mar 2021
Author: Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M et al.
Availability: Free full text
Ref.: J Immunother Cancer. 2021 Mar;9(3):e001504.
DOI:10.1136/jitc-2020-001504
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest